A 47-year-old woman with branch retinal arterial occlusion treated with sodium ozagrel is described. The patient presented with acute visual field loss in her right eye. Blood tests demonstrated the elevation of β-thromboglobulin and platelet factor 4. Sodium ozagrel, a thromboxane A2 synthetase inhibitor, 160 mg daily was administered for 14 days. This treatment prevented exacerbation of retinal arterial thrombosis and produced a marked improvement in the visual field loss. Sodium ozagrel may be a useful drug in the treatment of acute retinal arterial occlusion thought to be caused by thrombosis.
KnoopKTrottA: Ophthalmologic procedures in the emergency department–Part I: Immediate sight-saving procedures. Acad Emerg Med1994; 1: 408–412.
4.
ReichelE: Vitreoretinal emergencies. Am Fam Physician1995; 52: 1415–1419.
5.
NeedlemanPARazJAFerrendelliJA: Application of imidazole as a selective inhibitor of thromboxane synthetase in human platelets. Proc Natl Acad Sci USA1977; 74: 1716–1720.
6.
HirakuSTaniguchiKWakitaniK: Pharmacological studies on the TXA2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-Propenoic acid (OKY-046). Jpn J Pharmacol1986; 41: 393–401.
7.
NaitoJKomatsuHUjiieA: Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets. Eur J Pharmacol1983; 91: 41–48.
8.
OhtomoEKutsuzawaTKogureK: Clinical usefulness of OKY-046 on the acute stage of cerebral thrombosis. Double-blind trial in comparison with placebo (in Japanese, English abstract). J Clin Ther Med1991; 7: 353–388.
9.
SuzukiSIwabuchiTTanakaT: Prevention of cerebral vasospasm with OKY-046 an imidazole derivative and a thromboxane synthetase inhibitor. A preliminary co-operative clinical study. Acta Neurochir1985; 77: 133–141.
10.
Tokiyoshi K, Ohnishi T, Nii Y: Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage. Surg Neurol1991; 36: 112–118.
